Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3204 USD | +0.12% | -2.32% | -93.89% |
Financials (USD)
Sales 2024 * | 1.58M | Sales 2025 * | 807K | Capitalization | 19.53M |
---|---|---|---|---|---|
Net income 2024 * | -87M | Net income 2025 * | -86M | EV / Sales 2024 * | 12.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 24.2 x |
P/E ratio 2024 * |
-0.25
x | P/E ratio 2025 * |
-0.3
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.37% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | +0.13% | ||
1 week | -2.32% | ||
Current month | -2.32% | ||
1 month | -17.10% | ||
3 months | -93.97% | ||
6 months | -91.85% | ||
Current year | -93.89% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.3204 | +0.13% | 1,046,084 |
24-06-06 | 0.32 | 0.00% | 2,195,318 |
24-06-05 | 0.32 | -1.17% | 1,633,188 |
24-06-04 | 0.3238 | -0.34% | 2,557,824 |
24-06-03 | 0.3249 | -0.95% | 2,214,637 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-93.89% | 19.53M | |
+51.85% | 57.87B | |
+41.36% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- LYRA Stock